Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT immunogenicity and co-administration with Prevenar 13 in toddlers
NCT01939158Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen in meningococcal infection, sponsored by Pfizer. Primary endpoints: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement Antibody (rSBA) Titers >=1:8 at Year 5, Percentage of Participants With rSBA Titers >=1:128 at Year 5 and 2 more. Started Oct 2013; status: completed.
02
Drugs
Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT01939158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939158.